Making cancer screening earlier,
more accurate, accessible and convenient.
LAMH (Laboratory for Advanced Medicine & Health Group) is an innovative enterprise focused on AI-driven cancer early screening and diagnosis. It was co-founded by international business leaders, top scientists and authoritative doctors, with the concept of "making cancer screening earlier, more accurate, accessible and convenient". Since its establishment, LAMH has raised more than 1 billion RMB in financing. As a global leader in cancer early screening and diagnosis, LAMH cooperates with multiple top cancer centers, universities, and affiliated hospitals. It has published related research results in top international journals such as Nature, Science, Cell and its sub-journals, PNAS, and has established a full product pipeline for early screening and diagnosis of liver cancer, colorectal cancer, lung cancer, and pan-cancer. With the help of AI-driven technology, LAMH is committed to providing users with a full life-cycle service, combining genomics and clinical medicine theory.
LAMH, an independent entity in China, has its headquarters located in Guangzhou Pazhou Center Business District, a research and registration center in Beijing Economic and Technological Development Zone, Southern and Northern Medical Testing Laboratories (ICL) that meet PCR and NGS standards in Guangzhou Biological Island and Beijing Yizhuang respectively, and an IVD GMP factory through NMPA assessment in Guangzhou Science City. Helio Genomics, an independent entity in the United States, is headquartered in Irvine, California, and has a central laboratory certified by CLIA and CAP in Indiana.
Mission
Making cancer screening earlier,
more accurate, accessible and convenient.
Vision
A technology-driven global leader
in early cancer detection.
Values
Result-oriented, customer-centric,
and people-oriented.
Mr. Zeyue Zhang has a rich background in Business, clinical medicine and biotechnology in the gene industry; He has management experience in start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He has worked in well-known domestic gene companies such as BGI, BoA, Roche and Novartis, as well as the sales department of well-known multinational pharmaceutical companies.
Bachelor of Medicine, Southern Medical University;
Executive Master of Business Administration (EMBA) from China Europe International Business
School (CEIBS).
Dr. Shu Li is a successful entrepreneur in the biomedical field. He served as senior vice president of Conexant Systems, vice president and general manager of Honeywell Commercial Spare Parts, and held senior management positions in Motorola and Intel. Dr. Li Shu is a member of the Advisory Board of the University of California, Irvine (Business School), and has also served as a faculty member at the University of Arizona. He holds 6 US and international patents.
Bachelor of Automatic Control from Huazhong University of Science and Technology;
Degree in Electrical Engineering from the University of Illinois at Urbana-Champaign;
PhD in Applied Science from Harvard University.